A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin

{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T16:36:50Z', 'timestamp': 1711643810150}, 'reference-count': 21, 'publisher': 'Elsevier BV', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.ijantimicag.2020.106248', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 28]], 'date-time': '2020-11-28T16:15:37Z', 'timestamp': 1606580137000}, 'page': '106248', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 40, 'title': 'A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ' 'ivermectin', 'prefix': '10.1016', 'volume': '57', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-8841-7545', 'authenticated-orcid': False, 'given': 'Martin D.', 'family': 'Hellwig', 'sequence': 'first', 'affiliation': []}, {'given': 'Anabela', 'family': 'Maia', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijantimicag.2020.106248_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '470', 'DOI': '10.1016/S0140-6736(20)30185-9', 'article-title': 'A novel coronavirus outbreak of global health concern', 'volume': '395', 'author': 'Wang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '692', 'DOI': '10.1056/NEJMp2000929', 'article-title': 'A novel coronavirus emerging in China—key questions for impact ' 'assessment', 'volume': '382', 'author': 'Munster', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0003', 'series-title': 'COVID-19 coronavirus pandemic', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0004', 'article-title': 'Polarization and public health: partisan differences in social ' 'distancing during the coronavirus pandemic. Working Paper 26946', 'author': 'Allcott', 'year': '2020', 'journal-title': 'National Bureau of Economic Research'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0005', 'doi-asserted-by': 'crossref', 'DOI': '10.1088/1478-3975/ab9bf5', 'article-title': 'The COVID-19 pandemic: growth patterns, power law scaling, and ' 'saturation', 'volume': '17', 'author': 'Singer', 'year': '2020', 'journal-title': 'Phys Biol'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '14', 'DOI': '10.1126/science.368.6486.14', 'article-title': 'Vaccine designers take first shots at COVID-19', 'volume': '368', 'author': 'Cohen', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '170', 'DOI': '10.1016/j.jacbts.2016.03.002', 'article-title': 'Drugs, devices, and the FDA: Part 1: an overview of approval processes ' 'for drugs', 'volume': '1', 'year': '2016', 'journal-title': 'JACC Basic Transl Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '14', 'DOI': '10.1038/s41421-020-0153-3', 'article-title': 'Network-based drug repurposing for novel coronavirus ' '2019-nCoV/SARS-CoV-2', 'volume': '6', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0009', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105932', 'article-title': 'Chloroquine and hydroxychloroquine as available weapons to fight ' 'COVID-19', 'volume': '55', 'author': 'Colson', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0010', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101615', 'article-title': 'Remdesivir as a possible therapeutic option for the COVID-19', 'volume': '34', 'author': 'Al-Tawfiq', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0011', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '199', 'DOI': '10.1046/j.1472-8206.2003.00170.x', 'article-title': 'Ivermectin and filariasis', 'volume': '17', 'author': 'Richard-Lenoble', 'year': '2003', 'journal-title': 'Fundam Clin Pharmacol'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '133', 'DOI': '10.1056/NEJM198507183130301', 'article-title': 'Comparison of ivermectin and diethylcarbamazine in the treatment of ' 'onchocerciasis', 'volume': '313', 'author': 'Greene', 'year': '1985', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0014', 'doi-asserted-by': 'crossref', 'DOI': '10.2139/ssrn.3636557', 'article-title': 'Ivermectin for COVID-19 treatment: clinical response at quasi-threshold ' 'doses via hypothesized alleviation of CD147-mediated vascular occlusion', 'author': 'Scheim', 'year': '2020', 'journal-title': 'SSRN'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.2139/ssrn.3631261', 'article-title': 'ICON (Ivermectin in COvid Nineteen) Study: use of ivermectin is ' 'associated with lower mortality in hospitalized patients with COVID-19', 'author': 'Rajter', 'year': '2020', 'journal-title': 'SSRN'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'a systematic review from antiviral effects to COVID-19 complementary ' 'regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0017', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pntd.0006020', 'article-title': 'Safety and pharmacokinetic profile of fixed-dose ivermectin with an ' 'innovative 18mg tablet in healthy adult volunteers', 'volume': '12', 'author': 'Muñoz', 'year': '2018', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0018', 'series-title': 'PCT Databank', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1002/cpt.1889', 'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'volume': '108', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0020', 'series-title': 'Ivermectin and abamectin', 'first-page': '113', 'article-title': 'Pharmacokinetics of ivermectin in animals and humans', 'author': 'Fink', 'year': '1989'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0021', 'series-title': 'COVID-19 and ivermectin intended for animals', 'year': '2020'}], 'container-title': 'International Journal of Antimicrobial Agents', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304684?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304684?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 3, 8]], 'date-time': '2021-03-08T09:41:34Z', 'timestamp': 1615196494000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0924857920304684'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 21, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 1]]}}, 'alternative-id': ['S0924857920304684'], 'URL': 'http://dx.doi.org/10.1016/j.ijantimicag.2020.106248', 'relation': {}, 'ISSN': ['0924-8579'], 'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Antimicrobial Agents', 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'A COVID-19 prophylaxis? Lower incidence associated with prophylactic ' 'administration of ivermectin', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Antimicrobial Agents', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijantimicag.2020.106248', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. ' 'All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '106248'}